Sun Pharma Advanced Research Co Ltd
NSE:SPARC
Net Margin
Sun Pharma Advanced Research Co Ltd
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| IN |
S
|
Sun Pharma Advanced Research Co Ltd
NSE:SPARC
|
49.8B INR |
-477%
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
723.1B USD |
23%
|
|
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP |
-4%
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
404.4B USD |
25%
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
206.4B CHF |
14%
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.5T DKK |
35%
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
173B GBP |
14%
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
183.4B CHF |
25%
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
207.9B USD |
27%
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
183.8B USD |
-126%
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
138.1B USD |
13%
|
Sun Pharma Advanced Research Co Ltd
Glance View
Sun Pharma Advanced Research Co. Ltd. is a bio-pharmaceutical company, which engages in the research and development of pharmaceuticals. The company is headquartered in Mumbai, Maharashtra. The company went IPO on 2007-07-18. The firm is engaged in the business of research and development (R&D) of pharmaceutical products to meet unmet medical needs in the areas of oncology, neurodegeneration and immunology. The company develops new chemical entities (NCE), new biological entities (NDDS) and reformulated products. Its NCE includes SCC-138, SCO-088, SCO-120 and SCD-044. Its NDDS includes Wrap Matrix technology, Lipexelle technology and TearAct Technology. Wrap Matrix technology, which is useful to develop controlled-release tablets. The firm has developed Elepsia XR, using Wrap Matrix technology. Lipexelle technology for ophthalmic formulations. The company has developed Xelpros, a BAK-free latanoprost eye drops developed using Lipexelle technology. Xelpros is commercialized by the Company’s partner in the United States. The company developed PDP-716 eye drops for the treatment of glaucoma based on its TearAct technology.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on Sun Pharma Advanced Research Co Ltd's most recent financial statements, the company has Net Margin of -477.2%.
You don't have any saved screeners yet